Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Valneva SE is a biotechnology company specializing in the development and commercialization of vaccines for infectious diseases. The company's portfolio includes vaccines for diseases such as Japanese encephalitis and cholera. Valneva is actively engaged in developing vaccines for Lyme disease and chikungunya. Founded in 2013 through the merger of Intercell AG and Vivalis, Valneva is headquartered in Saint-Herblain, France. The company operates primarily in Europe but has a global reach through various strategic partnerships and licensing agreements. Valneva's competitive strength lies in its focus on addressing unmet medical needs with its diverse pipeline of innovative vaccine candidates.
View stock
VS
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
View stock

Stock highlights

Stock comparison highlights
Stock name
Valneva SEEli Lilly
Last price
€2.39$1,306.69
Currency
EUR
USD
€455M$1.2T
-43.86
-€0.88$29.79
1.370.45
0$6.69
00.53%
Sector
HealthHealth
Employees
62050,000
Ticker
€VLA$LLY
Primary listing
PARNYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in €VLA or $LLY on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.